165 related articles for article (PubMed ID: 38453365)
1. Oncogenic mutations of KRAS modulate its turnover by the CUL3/LZTR1 E3 ligase complex.
Damianou A; Liang Z; Lassen F; Vendrell I; Vere G; Hester S; Charles PD; Pinto-Fernandez A; Santos A; Fischer R; Kessler BM
Life Sci Alliance; 2024 May; 7(5):. PubMed ID: 38453365
[TBL] [Abstract][Full Text] [Related]
2. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
3. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.
Chen CC; Er TK; Liu YY; Hwang JK; Barrio MJ; Rodrigo M; Garcia-Toro E; Herreros-Villanueva M
PLoS One; 2013; 8(2):e55793. PubMed ID: 23437064
[TBL] [Abstract][Full Text] [Related]
4. Oncogenic KRAS engages an RSK1/NF1 pathway to inhibit wild-type RAS signaling in pancreatic cancer.
Cheng DK; Oni TE; Thalappillil JS; Park Y; Ting HC; Alagesan B; Prasad NV; Addison K; Rivera KD; Pappin DJ; Van Aelst L; Tuveson DA
Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34021083
[TBL] [Abstract][Full Text] [Related]
5. Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation.
Chen S; Vedula RS; Cuevas-Navarro A; Lu B; Hogg SJ; Wang E; Benbarche S; Knorr K; Kim WJ; Stanley RF; Cho H; Erickson C; Singer M; Cui D; Tittley S; Durham BH; Pavletich TS; Fiala E; Walsh MF; Inoue D; Monette S; Taylor J; Rosen N; McCormick F; Lindsley RC; Castel P; Abdel-Wahab O
Cancer Discov; 2022 Oct; 12(10):2434-2453. PubMed ID: 35904492
[TBL] [Abstract][Full Text] [Related]
6. Mutation-Specific and Common Phosphotyrosine Signatures of
Tahir R; Renuse S; Udainiya S; Madugundu AK; Cutler JA; Nirujogi RS; Na CH; Xu Y; Wu X; Pandey A
J Proteome Res; 2021 Jan; 20(1):670-683. PubMed ID: 32986951
[No Abstract] [Full Text] [Related]
7. Clinical Significance of Somatic Mutations in RAS/RAF/MAPK Signaling Pathway in Moroccan and North African Colorectal Cancer Patients.
Benmokhtar S; Laraqui A; El Boukhrissi F; Hilali F; Bajjou T; Jafari M; El Zaitouni S; Baba W; El Mchichi B; Elannaz H; Lahlou IA; Chahdi H; Oukabli M; Mahfoud T; Tanz R; Ichou M; Ennibi K; Dakka N; Sekhsokh Y
Asian Pac J Cancer Prev; 2022 Nov; 23(11):3725-3733. PubMed ID: 36444585
[TBL] [Abstract][Full Text] [Related]
8. LZTR1 facilitates polyubiquitination and degradation of RAS-GTPases.
Abe T; Umeki I; Kanno SI; Inoue SI; Niihori T; Aoki Y
Cell Death Differ; 2020 Mar; 27(3):1023-1035. PubMed ID: 31337872
[TBL] [Abstract][Full Text] [Related]
9. Molecular assemblies of the catalytic domain of SOS with KRas and oncogenic mutants.
Moghadamchargari Z; Shirzadeh M; Liu C; Schrecke S; Packianathan C; Russell DH; Zhao M; Laganowsky A
Proc Natl Acad Sci U S A; 2021 Mar; 118(12):. PubMed ID: 33723061
[TBL] [Abstract][Full Text] [Related]
10. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
[TBL] [Abstract][Full Text] [Related]
11. KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
Rabara D; Tran TH; Dharmaiah S; Stephens RM; McCormick F; Simanshu DK; Holderfield M
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22122-22131. PubMed ID: 31611389
[No Abstract] [Full Text] [Related]
12. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
Kundu S; Ali MA; Handin N; Conway LP; Rendo V; Artursson P; He L; Globisch D; Sjöblom T
J Exp Clin Cancer Res; 2021 Jul; 40(1):225. PubMed ID: 34233735
[TBL] [Abstract][Full Text] [Related]
13. Non-Redundant and Overlapping Oncogenic Readouts of Non-Canonical and Novel Colorectal Cancer KRAS and NRAS Mutants.
Alcantara KMM; Malapit JRP; Yu RTD; Garrido JAMG; Rigor JPT; Angeles AKJ; Cutiongco-de la Paz EM; Garcia RL
Cells; 2019 Dec; 8(12):. PubMed ID: 31816869
[TBL] [Abstract][Full Text] [Related]
14. Acquired Resistance to KRAS
Awad MM; Liu S; Rybkin II; Arbour KC; Dilly J; Zhu VW; Johnson ML; Heist RS; Patil T; Riely GJ; Jacobson JO; Yang X; Persky NS; Root DE; Lowder KE; Feng H; Zhang SS; Haigis KM; Hung YP; Sholl LM; Wolpin BM; Wiese J; Christiansen J; Lee J; Schrock AB; Lim LP; Garg K; Li M; Engstrom LD; Waters L; Lawson JD; Olson P; Lito P; Ou SI; Christensen JG; Jänne PA; Aguirre AJ
N Engl J Med; 2021 Jun; 384(25):2382-2393. PubMed ID: 34161704
[TBL] [Abstract][Full Text] [Related]
15. Oncogenic KRAS suppresses store-operated Ca
Pierro C; Zhang X; Kankeu C; Trebak M; Bootman MD; Roderick HL
Cell Calcium; 2018 Jun; 72():70-80. PubMed ID: 29748135
[TBL] [Abstract][Full Text] [Related]
16. The GSK3 kinase and LZTR1 protein regulate the stability of Ras family proteins and the proliferation of pancreatic cancer cells.
Palanivel C; Chaudhary N; Seshacharyulu P; Cox JL; Yan Y; Batra SK; Ouellette MM
Neoplasia; 2022 Mar; 25():28-40. PubMed ID: 35114566
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS
Charitou T; Srihari S; Lynn MA; Jarboui MA; Fasterius E; Moldovan M; Shirasawa S; Tsunoda T; Ueffing M; Xie J; Xin J; Wang X; Proud CG; Boldt K; Al-Khalili Szigyarto C; Kolch W; Lynn DJ
Br J Cancer; 2019 Jul; 121(1):37-50. PubMed ID: 31133691
[TBL] [Abstract][Full Text] [Related]
19. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic KRAS creates an aspartate metabolism signature in colorectal cancer cells.
Doubleday PF; Fornelli L; Ntai I; Kelleher NL
FEBS J; 2021 Dec; 288(23):6683-6699. PubMed ID: 34227245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
